EA
Anavex Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ANAVEX®2-73 (blarcamesine) | Alzheimer's Disease Dementia | Phase 2/3 |
| ANAVEX®1-41 | Neurodegenerative Diseases | Preclinical |
Leadership Team at Anavex Life Sciences
CU
Christopher U. Missling, PhD
President, Chief Executive Officer, and Director
SB
Sandra Boenisch
Senior Vice President, Chief Financial Officer
WE
Walter E. Kaufmann, MD
Chief Medical Officer
SN
Stephan N. Schaefer, MD
Executive Vice President, Global Clinical Development
AS
Athanasios Skarpelos
Director